Author

Robert H. Vonderheide

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract IA007: Getting ahead of the tumor: Interception approaches for pancreas cancer

Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...

Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al. · Cancer Research · 0 citations

Sep 2026

Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing

Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...

Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al. · Cancer Research · 0 citations

Review Open access Sep 2026

Developing neoantigen cancer vaccines: where are we now?

The success of immunotherapies such as immune checkpoint blockade and engineered T-cells has demonstrated the immune system’s anticancer potential. Although prophylactic vaccines against oncogenic viruses such as human papillomavirus prevent cancer by blocking infection, therapeutic vaccines targeting tumour-associated...

N. Markosyan, Robert H. Vonderheide · Nature Communications · 0 citations